References
- Caraceni A , HanksG, KaasaS et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 13 , e58–e68 (2012).
- Mercadante S , RadbruchL, CaraceniA et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94 , 832–839 (2002).
- Portenoy RK , BennettDS, RauckR et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J. Pain 7 , 583–591 (2006).
- Markman JD . Not so fast: the reformulation of fentanyl and breakthrough chronic noncancer pain. Pain136 , 227–229 (2008).
- Pflughaupt M , ScharnagelR, GossrauG et al. Physicians‘ knowledge and attitudes concerning the use of opioids in the treatment of chronic cancer and non-cancer pain. Schmerz 24 , 267–275 (2010).
- Schütze A , KaiserU, EttrichU et al. Evaluation of a multimodal pain therapy at the University Pain Centre Dresden. Schmerz 23 , 609–617 (2009).
- Twycross R . Cancer pain classification. Acta Anaesthesiol. Scand.41 , 141–145 (1997).
- Knudsen AK , BrunelliC, KaasaS et al. Which variables are associated with pain intensity and treatment response in advanced cancer patients? – Implications for a future classification system for cancer pain. Eur. J. Pain 15 , 320–327 (2011).
- Knudsen AK , BrunelliC, KlepstadP et al. Which domains should be included in a cancer pain classification system? Analyses of longitudinal data. Pain 153 , 696–703 (2012).
▪ Website
- Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Kreuzschmerz – Langfassung. Version 1.X. (2010). www.versorgungsleitlinien.de/themen/kreuzschmerz (Accessed 26February2012)